Phase 3Active, not recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes (KaiNETIC-2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Sponsor
- Kailera (Industry)
- Enrolment
- 1,270 enrolled
- Conditions
- Obesity With Diabetes; Overweight With Diabetes
- Interventions
- Ribupatide; Placebo
- Ages
- adults, older adults
- Registry
- NCT07284901
Full record on ClinicalTrials.gov
From the registry
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
Primary outcomes
- Doses 3 and 4 of Ribupatide Versus Placebo: Percent Change From Baseline in Body Weight at Week 76
- Doses 3 and 4 of Ribupatide Versus Placebo: Change From Baseline in HbA1c at Week 76
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered